A PHASE 2A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS

Brief description of study

The purpose of this research study is to compare the effects of the study drug, PF-06823859 with a placebo to find out which is better for treating Dermatomyositis (DM). PF-06823859 is an investigational drug that is not approved by the U.S. Food and Drug Administration (FDA). This study will also be using a placebo, looks like the study drug but does not contain any drug. Researchers use a placebo to see if the study drug works better or is safer than not taking anything. The Study Drug is a type of drug called a biologic. Biologics are made up of proteins that can help the body's immune response. Biologics typically have a long half-life which means they stay in your body working for a long time. They are given by injection either into your skin or into your vein. The Study Drug is designed to fight inflammation by working directly on the immune system, by neutralizing some of the naturally occurring beta interferon.


Clinical Study Identifier: s17-00937
ClinicalTrials.gov Identifier: NCT03181893
Principal Investigator: Alisa N Femia.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.